Maze Therapeutics, Inc. (MAZE)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
27.44 USD
-1.16
(-4.056%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 27.97 +0.53 (1.931%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:37 a.m. EDT
The investment case here is defined by a stark disconnect between aggressive analyst optimism and deteriorating business reality. On paper, Wall Street is pricing in a massive comeback, with targets nearly four times the current price, yet the company is burning through cash at a rapid pace with no revenue to speak of and negative returns on equity. The balance sheet, while currently liquid due to cash holdings, is not generating free cash flow and relies entirely on capital markets to survive. This fundamental fragility explains the heavy options positioning in deep puts; traders are hedging against a failure to raise capital or deliver clinical results, not betting on organic growth. The recent price bounce appears to be a technical relief rally off lows rather than a reversal of the secular downtrend, leaving the stock in a precarious holding pattern where the gap between expectation and execution remains dangerously wide. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.071712 |
| AutoARIMA | 0.083308 |
| AutoETS | 0.083359 |
| MSTL | 0.083860 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.25 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.139 |
| Excess Kurtosis | -0.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.335 |
| Revenue per Share | 0.377 |
| Market Cap | 1,524,269,184 |
| Forward P/E | -8.64 |
| Website | https://www.mazetx.com |
As of Aug. 22, 2026, 5:37 a.m. EDT: Speculators are positioning for a range-bound outcome with a distinct skew toward downside protection. While there is notable volume in out-of-the-money calls for November and January expirations, the open interest is heavily concentrated in deep in-the-money puts (strikes 15 and 17.5), suggesting a 'crash' hedge rather than a rally bet. The implied volatility is elevated on these protective strikes, indicating fear of a significant drop below current levels.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8668407 |
| Address1 | 171 Oyster Point Blvd |
| Address2 | Suite 300 |
| All Time High | 53.65 |
| All Time Low | 6.71 |
| Ask | 35.55 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 360,170 |
| Average Daily Volume3 Month | 553,962 |
| Average Volume | 553,962 |
| Average Volume10Days | 360,170 |
| Bid | 19.91 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 8.164 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 27.44 |
| Current Ratio | 18.31 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 28.46 |
| Day Low | 27.31 |
| Debt To Equity | 13.335 |
| Display Name | Maze Therapeutics |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -143,707,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.167 |
| Enterprise To Revenue | 58.68 |
| Enterprise Value | 1,173,605,120 |
| Eps Current Year | -2.72626 |
| Eps Forward | -3.17549 |
| Eps Trailing Twelve Months | -2.44 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 28.5728 |
| Fifty Day Average Change | -1.1327991 |
| Fifty Day Average Change Percent | -0.039646067 |
| Fifty Two Week Change Percent | 86.684074 |
| Fifty Two Week High | 53.65 |
| Fifty Two Week High Change | -26.210001 |
| Fifty Two Week High Change Percent | -0.4885368 |
| Fifty Two Week Low | 14.157 |
| Fifty Two Week Low Change | 13.283001 |
| Fifty Two Week Low Change Percent | 0.93826383 |
| Fifty Two Week Range | 14.157 - 53.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,738,333,800,000 |
| Float Shares | 36,767,994 |
| Forward Eps | -3.17549 |
| Forward P E | -8.641187 |
| Free Cashflow | -63,627,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 141 |
| Fullday Change | -1.16 |
| Fullday Change Percent | -4.05594 |
| Fullday Price | 27.97 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 1.0 |
| Gross Profits | 20,000,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.014579999 |
| Held Percent Institutions | 1.06784 |
| Implied Shares Outstanding | 55,549,168 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-01-31 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California. |
| Long Name | Maze Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,524,269,184 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_602685968 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -133,590,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,588,706,204 |
| Number Of Analyst Opinions | 11 |
| Open | 28.46 |
| Operating Cashflow | -106,538,000 |
| Operating Margins | -7.2806 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 850 5070 |
| Post Market Change | 0.5299988 |
| Post Market Change Percent | 1.9314824 |
| Post Market Price | 27.97 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 28.6 |
| Price Eps Current Year | -10.065071 |
| Price Hint | 2 |
| Price To Book | 3.3610978 |
| Price To Sales Trailing12 Months | 76.21346 |
| Profit Margins | 0.0 |
| Quick Ratio | 18.026 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.08333 |
| Region | US |
| Regular Market Change | -1.16 |
| Regular Market Change Percent | -4.05594 |
| Regular Market Day High | 28.46 |
| Regular Market Day Low | 27.31 |
| Regular Market Day Range | 27.31 - 28.46 |
| Regular Market Open | 28.46 |
| Regular Market Previous Close | 28.6 |
| Regular Market Price | 27.44 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 250,048 |
| Return On Assets | -0.21794 |
| Return On Equity | -0.37348998 |
| Revenue Per Share | 0.377 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 55,549,168 |
| Shares Percent Shares Out | 0.1078 |
| Shares Short | 5,988,933 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,525,278 |
| Short Name | Maze Therapeutics, Inc. |
| Short Percent Of Float | 0.121400006 |
| Short Ratio | 16.24 |
| Source Interval | 15 |
| State | CA |
| Symbol | MAZE |
| Target High Price | 110.0 |
| Target Low Price | 46.0 |
| Target Mean Price | 62.54545 |
| Target Median Price | 55.0 |
| Total Cash | 411,087,008 |
| Total Cash Per Share | 7.4 |
| Total Debt | 60,423,000 |
| Total Revenue | 20,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 34.38215 |
| Two Hundred Day Average Change | -6.942148 |
| Two Hundred Day Average Change Percent | -0.20191142 |
| Type Disp | Equity |
| Volume | 250,048 |
| Website | https://www.mazetx.com |
| Zip | 94,080 |